The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV
Overview
While Patient-controlled analgesia (PCA) has the advantage of effectively reducing the degree of postoperative pain, it can also affect the patient's outcome by several adverse effects such as postoperative nausea and vomiting (PONV). Especially for high risk group of patients for PONV, the ideal regimen for sufficient analgesia with minimal adverse effect needs to be sought. Propacetamol is known for its effective, rapid analgesia, opioid-sparing effect, and is used widely for post operative pain management. This study aims to see the opioid-sparing effect and the degree of PONV when propacetamol is added to PCA for high risk PONV patients.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
- Masking: Triple (Participant, Care Provider, Investigator)
- Study Primary Completion Date: March 2015
Interventions
- Drug: Propacetamol
- total 4g of Propacetamol added to patient’s PCA regimen
- Drug: PCA regimen
Arms, Groups and Cohorts
- Experimental: Propacetamol
- Placebo Comparator: PCA regimen
- routine PCA drug
Clinical Trial Outcome Measures
Primary Measures
- Incidence of PONV
- Time Frame: from immediate postop to 24 hours after the surgery
- Incidence of postoperative nausea, vomiting – Number of events
Participating in This Clinical Trial
Inclusion Criteria
1. Patients scheduled for either 1-2 level spine fusion or laminectomy 2. ASA (American Society of Anesthesiology) physical status 1 or 2 3. Non-smoking female patients, between the age 20 and 65 Exclusion Criteria:
1. Administration of any anti-emetic agents within 24 hours prior to surgery 2. Administration of any opioid agents within 7 days prior to surgery 3. Regular administration of any steroid agents 4. Drug or alcohol-abuser 5. Patients with bowel movement disorder, liver or renal impairment, insulin-dependent diabetes. Patients who are pregnant, illiterate, or foreign. 6. Patients administered to Intensive Care Unit after surgery
Gender Eligibility: Female
Minimum Age: 20 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Yonsei University
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.